One fund just doubled down on a beaten-down tax-tech leader—here’s what they may be seeing that the market isn’t.

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without regular ...

News headlines Vertex Pharmaceuticals is experiencing notable growth driven by its expanding pipeline and strong market interest, particularly in gene therapies. Recent clinical data and regulatory ...

Editorial Note: We earn a commission from partner links on Forbes Advisor. Commissions do not affect our editors' opinions or evaluations. Disclaimer: Calculator results and default inputs are ...

convert the numbers from standard form into decimal form or ordinary numbers complete the calculation convert the answer back into standard form Calculate \((4 \times 10^9) \times (7 \times 10^{-3})\) ...

See how your savings and investment account balances can grow with the magic of compound interest. Many, or all, of the products featured on this page are from our advertising partners who compensate ...

Most stock quote data provided by BATS. US market indices are shown in real time, except for the S&P 500 which is refreshed every two minutes. All times are ET ...

Learn how to gain control of your saving and spending Are you struggling to keep your spending below your income? Do you strategize about how to increase your savings? Our free budgeting calculator ...